Clinical cohorts indicate that estrogen receptor–positive (ER+) breast cancer patients frequently develop bone metastasis 8–10 years after diagnosis, with as many as 20% of early-stage patients experiencing distant metastases following extended latency, suggesting prolonged dormancy of disseminated tumor cells (DTCs) in bone [19,184,185,186]. Here, ESR1 is linked to breast carcinoma.